Legend Biotech is a biopharmaceutical company that develops chimeric antigen receptor T cell (CAR-T) therapies to treat hematologic cancers and solid tumors. The company's lead and only approved product is CARVYKTI (cilta-cel), a CAR-T therapy for multiple myeloma and other blood cancers, which is commercialized globally through a collaboration with Janssen and sold across the United States, European Union, and other markets. Legend Biotech generates revenue from CARVYKTI product sales and milestone payments under its partnership with Janssen, and reinvests earnings into manufacturing expansion, clinical trials for pipeline candidates (including earlier-stage CAR-T and CAR-NK therapies for solid tumors and autoimmune diseases), and commercial development aimed at expanding CARVYKTI into earlier treatment lines and potentially first-line use.